Save Product
Product Details
Synonyms
TNFRSF4, OX40, CD134, OX40L receptor, ACT35, TXGP1L
Source
Mouse OX40, Fc Tag (OX0-M5259) is expressed from human 293 cells (HEK293). It contains AA Val 20 - Pro 211 (Accession # NP_035789).
Predicted N-terminus: Val 20
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 47.9 kDa. The protein migrates as 55-70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Mouse OX40, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Mouse OX40, Fc Tag (Cat. No. OX0-M5259) is more than 95% and the molecular weight of this protein is around 110-145 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Mouse OX40 Ligand, His Tag (Cat. No. TN4-M5241) at 0.5 μg/mL (100 μL/well) can bind Mouse OX40, Fc Tag (Cat. No. OX0-M5259) with a linear range of 0.2-16 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor receptor superfamily member 4
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
29 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
